This multi-modal biomarker study investigates the use of olfactory mucosa, blood, and urine samples for early identification of neurodegenerative disorders including Parkinson's disease (PD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and related conditions. The study recognizes that olfactory dysfunction is one of the earliest and most common features of neurodegenerative diseases, often predating motor symptoms by years, and seeks to develop sensitive biomarker panels for early detection.
The recognition that smell dysfunction precedes motor symptoms in synucleinopathies by many years has generated intense interest in developing olfactory-based diagnostic tools. This study represents a comprehensive approach to multi-analyte biomarker detection across different biological compartments, aiming to identify early detection markers that could enable disease-modifying interventions before irreversible neuronal loss occurs.
| Field |
Value |
| NCT ID |
NCT06846658 |
| Status |
Recruiting |
| Study Type |
Observational |
| Conditions |
Parkinson's Disease, PSP, MSA, Atypical Parkinsonism, Healthy Controls |
| Sample Types |
Olfactory mucosa, Blood, Urine |
| Primary Outcome |
Diagnostic accuracy of multi-analyte biomarker panel |
| Secondary Outcomes |
Sensitivity by disease stage, correlation with clinical measures |
The olfactory system provides a unique window into central nervous system pathology for several reasons:
- Direct anatomical connection: The olfactory tract projects directly from the olfactory bulb to the brain without a blood-brain barrier
- Vulnerable neurons: Olfactory receptor neurons are exposed to environmental toxins and undergo continuous regeneration
- Early involvement: The olfactory bulb is affected early in many neurodegenerative diseases
- Accessible sampling: Olfactory mucosa can be sampled with minimally invasive procedures
Hyposmia (reduced sense of smell) occurs in over 90% of Parkinson's disease patients, making it one of the most prevalent non-motor symptoms. Critically, olfactory dysfunction often precedes motor symptoms by 5-10 years:
- Idiopathic anosmia: Many patients diagnosed with idiopathic smell loss later develop PD
- Smell testing sensitivity: UPSIT (University of Pennsylvania Smell Identification Test) scores distinguish PD patients from controls with high sensitivity
- Prodromal markers: Olfactory dysfunction is included in proposed prodromal PD criteria
- Progression correlation: Smell loss correlates with disease severity and progression
Olfactory dysfunction in PSP is less severe than in PD but remains clinically significant:
- Prevalence: 40-60% of PSP patients demonstrate olfactory impairment
- Pattern difference: Unlike PD, PSP shows relatively preserved odor identification with impaired discrimination
- Anatomical basis: Olfactory bulb involvement reflects the broader tau pathology affecting brainstem structures
- Diagnostic utility: May help distinguish PSP from PD in uncertain cases
MSA shows olfactory dysfunction similar to PD:
- Prevalence: Approximately 60-70% of MSA patients demonstrate olfactory impairment
- Pattern overlap: Similar to PD, with both identification and discrimination affected
- Differentiation challenges: Olfactory testing alone cannot reliably distinguish MSA from PD
- Combined biomarkers: May be useful in multi-marker panels
The olfactory mucosa contains olfactory receptor neurons (ORNs) that project directly to the brain, making it an attractive source of CNS biomarkers:
- Aggregated α-syn: Detectable in olfactory mucosa of PD patients
- Seed activity: Tissue-based seeding assays show presence of pathological α-syn
- Diagnostic sensitivity: Variable across studies (50-80%)
- Specificity: Lower specificity due to presence in other conditions
- Sampling considerations: Requires specialized olfactory swab techniques
- Total tau: Elevated in neurodegenerative conditions
- Phosphorylated tau: Specific patterns in tauopathies like PSP
- Olfactory bulb pathology: Shows tau pathology in PSP and AD
- Correlation with disease: Levels may reflect disease burden
- Cytokines: IL-6, TNF-α detectable in olfactory mucosa
- Microglial markers: Reflect neuroinflammatory processes
- Diagnostic value: May indicate disease-specific inflammation patterns
Blood sampling offers a minimally invasive approach to biomarker detection:
- Axonal damage marker: Released upon axonal injury
- Elevated in PSP: Higher than in PD or controls
- Prognostic value: Correlates with disease progression
- Clinical utility: Approved for clinical use in some contexts
- Seed amplification: RT-QuIC and PMCA detect pathological α-syn
- Sensitivity: High sensitivity for synucleinopathies
- Specificity: Differentiates PD from controls
- Blood-brain barrier: Challenging but achievable detection
- Cytokines: TNF-α, IL-1β, IL-6 commonly elevated
- Chemokines: CCL2, CXCL10 implicated
- Microglial markers: sTREM2 in CSF, limited in blood
Urine offers a completely non-invasive sampling option:
- Oligomeric α-syn: Toxic species detectable in urine
- Oxidative modifications: Reflect oxidative stress in neurons
- Correlation studies: Variable correlation with disease state
- 8-OHdG: DNA oxidation product
- Isoprostanes: Lipid peroxidation markers
- Limited specificity: Elevated in many conditions
- Iron accumulation: Elevated in PD substantia nigra
- Urine levels: May reflect systemic accumulation
- Diagnostic value: Under investigation
¶ Study Design and Methodology
The study employs standardized collection protocols across all sample types:
- Patient preparation: Nasal examination to rule out local pathology
- Sampling location: Middle turbinate or olfactory cleft
- Collection device: Specialized cotton or nylon swabs
- Processing: Immediate freezing at -80°C
- Quality control: RNA integrity for molecular analyses
- Fasting state: Standardized collection timing
- Collection tubes: EDTA, heparin, and SST tubes
- Processing: Centrifugation within 2 hours
- Storage: Plasma/serum at -80°C
- Additional samples: PBMCs for cellular analyses
- Standardized timing: Morning void preferred
- Collection method: Mid-stream clean catch
- Processing: Aliquoting within 4 hours
- Creatinine normalization: For concentration comparisons
- Storage: Multiple aliquots at -80°C
The study employs multiple analytical platforms:
| Platform |
Target Analytes |
Advantages |
| ELISA |
Proteins, antibodies |
High throughput, validated |
| Simoa |
Ultra-sensitive proteins |
Detects low-abundance markers |
| RT-QuIC |
Aggregated proteins |
High sensitivity for seeds |
| Mass spectrometry |
Metabolomics, proteomics |
Unbiased discovery |
| qPCR |
Nucleic acids |
Genetic marker detection |
¶ Clinical Applications and Utility
The primary clinical utility lies in early disease detection:
- Prodromal identification: Patients with REM sleep behavior disorder (RBD) are at high risk
- Pre-motor diagnosis: Smell testing could identify at-risk individuals
- Disease modification: Early intervention opportunities
- Clinical trial enrichment: Identification of early-stage patients
Olfactory and systemic biomarkers may help differentiate between conditions:
- PD vs. PSP: Different patterns of olfactory loss and biomarker profiles
- PD vs. MSA: NfL levels and α-syn seeding differ
- Atypical vs. typical Parkinsonism: Combined biomarker panels
- AD vs. DLB: Different tau and α-syn profiles
Biomarkers may serve as progression markers:
- NfL trajectories: Correlate with clinical decline
- Olfactory change: Smell testing progression correlation
- Therapeutic monitoring: Response biomarkers for clinical trials
Early detection in PD is particularly important because:
- Pre-motor window: 5-10 years before diagnosis
- Neuroprotective trials: Early intervention may be more effective
- Dopaminergic preservation: Neurons lost by diagnosis
- Risk stratification: Family history and genetic risk
PSP presents unique challenges addressed by this study:
- Rapid progression: 7-9 year median survival
- Diagnostic delay: Average 2-3 years from symptom onset
- Atypical presentations: Richardson syndrome vs. variant PSP
- Treatment urgency: Early intervention critical
MSA biomarker development is crucial:
- Autonomic failure: Core diagnostic feature
- Differential from PD: Treatment and prognosis differ
- Progression markers: Need for objective measures
- Clinical trials: Patient selection and monitoring
The study contributes to biomarker validation following the ATN (Amyloid, Tau, Neurodegeneration) framework:
- Analytical validation: Assay precision, accuracy, reproducibility
- Clinical validation: Sensitivity, specificity, predictive values
- Clinical utility: Impact on patient outcomes
- Implementation: Feasibility, cost-effectiveness
Combining biomarkers across compartments enhances diagnostic accuracy:
- Complementary information: Different biological pathways
- Cross-validation: Independent biomarker confirmation
- Panel optimization: Weighted algorithms
- Machine learning: Pattern recognition approaches
¶ Expected Outcomes and Clinical Impact
The study is expected to generate:
- Validated biomarker panels: Multi-analyte combinations with high accuracy
- Sensitivity comparisons: Best performing markers for each condition
- Stage-specific profiles: Biomarkers for early vs. established disease
- Implementation guidelines: Clinical deployment protocols
Successful biomarker development would transform:
- Diagnostic accuracy: Earlier and more accurate diagnosis
- Clinical trial design: Enriched patient populations
- Therapeutic development: Progression and response markers
- Patient counseling: Prognostic information for patients
¶ Challenges and Limitations
- Olfactory sampling variability: Collection technique differences
- Biomarker stability: Degradation during processing
- Assay standardization: Inter-laboratory variation
- Background noise: Age-related changes and comorbidities
- Disease heterogeneity: Variable biomarker expression
- Stage dependence: Early vs. late disease differences
- Medication effects: Treatment-induced changes
- Comorbidities: Confounding conditions